Cargando…
Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging
Ovarian cancer is amongst the most common types of cancer in women, with a relatively low overall cure rate of approximately 30%. This is therefore an important incentive to urge for further research in order to maximize the chances of survival for these patients. Intraperitoneal chemotherapy with C...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956760/ https://www.ncbi.nlm.nih.gov/pubmed/27444797 http://dx.doi.org/10.1038/srep29999 |
_version_ | 1782444071090913280 |
---|---|
author | Laforce, Brecht Carlier, Charlotte Vekemans, Bart Villanova, Julie Tucoulou, Rémi Ceelen, Wim Vincze, Laszlo |
author_facet | Laforce, Brecht Carlier, Charlotte Vekemans, Bart Villanova, Julie Tucoulou, Rémi Ceelen, Wim Vincze, Laszlo |
author_sort | Laforce, Brecht |
collection | PubMed |
description | Ovarian cancer is amongst the most common types of cancer in women, with a relatively low overall cure rate of approximately 30%. This is therefore an important incentive to urge for further research in order to maximize the chances of survival for these patients. Intraperitoneal chemotherapy with Cisplatin is an effective treatement for ovarian cancer; however, many questions still remain concerning the ideal treatment protocol and tumor resistance towards the drug, which should be resolved for optimal application of this therapy. For the first time in-vivo grown tumors treated with both hyper- and normothermic intraperitoneal chemotherapy have been studied using nano-XRF spectroscopy to examine the platinum (Pt) distribution within the analyzed tissues. These measurements prove Pt resides predominantly outsides the cancer cells in the stroma of the tissue. These findings indicate the resistance mechanism of the cancer cells prevents Cisplatin from diffusing through their cell membranes. This is an important addition to the existing knowledge on the resistance mechanism providing insights which might help to overcome this effect. In our aim to find the optimal treatment protocol, no significant differences were found between the two examined procedures. A more extensive data set will be needed to draw definite conclusions. |
format | Online Article Text |
id | pubmed-4956760 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-49567602016-07-26 Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging Laforce, Brecht Carlier, Charlotte Vekemans, Bart Villanova, Julie Tucoulou, Rémi Ceelen, Wim Vincze, Laszlo Sci Rep Article Ovarian cancer is amongst the most common types of cancer in women, with a relatively low overall cure rate of approximately 30%. This is therefore an important incentive to urge for further research in order to maximize the chances of survival for these patients. Intraperitoneal chemotherapy with Cisplatin is an effective treatement for ovarian cancer; however, many questions still remain concerning the ideal treatment protocol and tumor resistance towards the drug, which should be resolved for optimal application of this therapy. For the first time in-vivo grown tumors treated with both hyper- and normothermic intraperitoneal chemotherapy have been studied using nano-XRF spectroscopy to examine the platinum (Pt) distribution within the analyzed tissues. These measurements prove Pt resides predominantly outsides the cancer cells in the stroma of the tissue. These findings indicate the resistance mechanism of the cancer cells prevents Cisplatin from diffusing through their cell membranes. This is an important addition to the existing knowledge on the resistance mechanism providing insights which might help to overcome this effect. In our aim to find the optimal treatment protocol, no significant differences were found between the two examined procedures. A more extensive data set will be needed to draw definite conclusions. Nature Publishing Group 2016-07-21 /pmc/articles/PMC4956760/ /pubmed/27444797 http://dx.doi.org/10.1038/srep29999 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Laforce, Brecht Carlier, Charlotte Vekemans, Bart Villanova, Julie Tucoulou, Rémi Ceelen, Wim Vincze, Laszlo Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging |
title | Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging |
title_full | Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging |
title_fullStr | Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging |
title_full_unstemmed | Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging |
title_short | Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging |
title_sort | assessment of ovarian cancer tumors treated with intraperitoneal cisplatin therapy by nanoscopic x-ray fluorescence imaging |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956760/ https://www.ncbi.nlm.nih.gov/pubmed/27444797 http://dx.doi.org/10.1038/srep29999 |
work_keys_str_mv | AT laforcebrecht assessmentofovariancancertumorstreatedwithintraperitonealcisplatintherapybynanoscopicxrayfluorescenceimaging AT carliercharlotte assessmentofovariancancertumorstreatedwithintraperitonealcisplatintherapybynanoscopicxrayfluorescenceimaging AT vekemansbart assessmentofovariancancertumorstreatedwithintraperitonealcisplatintherapybynanoscopicxrayfluorescenceimaging AT villanovajulie assessmentofovariancancertumorstreatedwithintraperitonealcisplatintherapybynanoscopicxrayfluorescenceimaging AT tucoulouremi assessmentofovariancancertumorstreatedwithintraperitonealcisplatintherapybynanoscopicxrayfluorescenceimaging AT ceelenwim assessmentofovariancancertumorstreatedwithintraperitonealcisplatintherapybynanoscopicxrayfluorescenceimaging AT vinczelaszlo assessmentofovariancancertumorstreatedwithintraperitonealcisplatintherapybynanoscopicxrayfluorescenceimaging |